Mirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, expected to drive market
The Biliary Atresia market growth is driven by factors like increase in the prevalence of Biliary Atresia, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Biliary Atresia market report also offers comprehensive insights into the Biliary Atresia market size, share, Biliary Atresia epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Biliary Atresia market size growth forward.
Some of the key highlights from the Biliary Atresia Market Insights Report:
Several key pharmaceutical companies, including Mirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, and others, are developing novel products to improve the Biliary Atresia treatment outlook.
DelveInsight estimates that in 2023, there were approximately 609 new cases of biliary atresia across the 7MM. The US accounted for nearly 56% of these cases, while EU4 and the UK represented 28%, and Japan accounted for 16%.
The biliary atresia market is poised for steady growth, with a strong compound annual growth rate (CAGR) expected from 2024 to 2034. Key factors driving this market expansion in the US include the increasing incidence of the disease, advancements in diagnostic methods, and growing acceptance of treatments. As a result, the biliary atresia drugs market is projected to experience significant growth, with a CAGR of 7.7%.
Despite these advancements, there is still a considerable treatment gap for biliary atresia due to the lack of approved drug therapies, with current treatments primarily relying on surgical procedures like the Kasai operation and liver transplantation. Given the substantial unmet needs in biliary atresia, several promising drugs are currently under development, targeting the condition, including odevixibat and obeticholic acid, among others.
As per DelveInsight analysis, the Biliary Atresia market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Biliary Atresia Market Landscape
Biliary Atresia Overview
Biliary atresia is a neonatal liver condition characterized by progressive obstruction and fibrosis of the extrahepatic biliary tree, along with fibrosis and inflammation of the liver tissue. The exact cause and mechanisms behind biliary atresia are still unclear. Recent research is exploring potential pathogenic factors, such as genetic predisposition, immune system involvement, and environmental factors like viruses and toxins. It is likely that there isn't a single cause but rather a range of harmful factors that could lead to a common outcome of extrahepatic bile duct obstruction and liver fibrosis.
The symptoms of biliary atresia typically emerge between 2 to 6 weeks of age. These include jaundice, which causes a yellowish tint to the skin and the whites of the eyes, pale stools, and dark urine. Infants may also experience abdominal swelling and/or an enlarged liver (hepatomegaly).
Do you know the treatment paradigms for different countries? Download our Biliary Atresia Market Sample Report
Biliary Atresia Epidemiology Insights
DelveInsight's epidemiology model estimates that in 2023, there were approximately 338 new cases of biliary atresia in the US, with this number expected to rise by 2034.
In 2023, there were about 17 cases of Type I, 7 cases of Type II, and 315 cases of Type III. Our projections indicate that these case numbers will change over the forecast period from 2024 to 2034.
Biliary Atresia Epidemiology Segmentation
DelveInsight's Biliary Atresia market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Biliary Atresia historical patient pools and forecasted Biliary Atresia patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Biliary Atresia Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:
Biliary Atresia Prevalence
Age-Specific Biliary Atresia Prevalence
Gender-Specific Biliary Atresia Prevalence
Diagnosed and Treatable Cases of Biliary Atresia
Visit for more @ Biliary Atresia Epidemiological Insights
Biliary Atresia Market Outlook
Biliary atresia is characterized by the fibro-proliferative obliteration of the biliary tree, which progressively leads to hepatic fibrosis, cirrhosis, and eventually end-stage liver failure. The treatment for biliary atresia is primarily surgical and generally involves two stages. In the first few months of life, a Hepatoportoenterostomy (commonly known as the "Kasai" procedure, with possible modifications) is performed to restore biliary flow to the intestine and minimize further liver damage. If this procedure fails or if the disease advances to biliary cirrhosis and life-threatening complications, a liver transplant is required, making biliary atresia the most common pediatric indication for liver transplantation.
In terms of postoperative care, management following Hepatoportoenterostomy includes interventions such as the use of choleretics and anti-inflammatory medications, nutritional rehabilitation, supplementation with fat-soluble vitamins, prevention of cholangitis, and management of portal hypertension and its related complications. Administration of choleretics like ursodeoxycholic acid (UDCA) is a standard practice in biliary atresia, although its clinical effectiveness has not been definitively proven. Taken orally, UDCA is a hydrophilic bile acid that alters the balance of bile acids toward hydrophilic forms. This is believed to stabilize cell membranes and reduce the generation of free radicals, thereby protecting mitochondria from damage.
High-energy supplements, such as glucose polymers or medium-chain triglyceride (MCT) oil, are added to formula or solid foods to support nutritional needs. MCT oil or MCT-based formulas are particularly useful because they are calorie-dense and can be easily absorbed by patients with cholestasis, as they do not require micellar solubilization. The treatment of biliary atresia is comprehensive, focusing on both addressing the underlying cause and managing symptoms to enhance patient comfort.
Biliary Atresia Emerging Drugs
BYLVAY (odevixibat): Ipsen
Obeticholic Acid: Intercept Pharmaceuticals
Biliary Atresia Key Companies
Mirium Pharmaceuticals
Albireo
Intercept Pharmaceuticals, and others
For more information, visit Biliary Atresia Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Biliary Atresia Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Biliary Atresia, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Biliary Atresia epidemiology in the 7MM
Biliary Atresia marketed and emerging therapies
Biliary Atresia companies
Biliary Atresia market drivers and barriers
Table of Contents:
1 Biliary Atresia Market Key Comprehensive Insights
2 Biliary Atresia Market Report Introduction
3 Competitive Intelligence Analysis for Biliary Atresia
4 Biliary Atresia Market Analysis Overview at a Glance
5 Executive Summary of Biliary Atresia
6 Biliary Atresia Epidemiology and Market Methodology
7 Biliary Atresia Epidemiology and Patient Population
8 Biliary Atresia Patient Journey
9 Biliary Atresia Treatment Algorithm, Biliary Atresia Current Treatment, and Medical Practices
10 Key Endpoints in Biliary Atresia Clinical Trials
11 Biliary Atresia Marketed Therapies
12 Biliary Atresia Emerging Therapies
13 Biliary Atresia: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Biliary Atresia
16 Biliary Atresia Market Key Opinion Leaders Reviews
18 Biliary Atresia Market Drivers
19 Biliary Atresia Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Biliary Atresia Epidemiology 2034
DelveInsight's "Biliary Atresia - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Biliary Atresia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Biliary Atresia Pipeline 2024
"Biliary Atresia Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Biliary Atresia market. A detailed picture of the Biliary Atresia pipeline landscape is provided, which includes the disease overview and Biliary Atresia treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
5 days ago
- Globe and Mail
Chronic Insomnia Market Growth Projections 2023-2032: DelveInsight Analysis
The Key Chronic Insomnia Companies in the market include - Janssen Research & Development, Takeda, and others. The Chronic Insomnia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics. DelveInsight's 'Chronic Insomnia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Insomnia, historical and forecasted epidemiology as well as the Chronic Insomnia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Chronic Insomnia Market Report: The Chronic Insomnia market size was valued ~USD 333 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032) Among the seven major markets (7MM), the United States represented 67.3% of the total market size for Chronic Insomnia in 2021. In the 7 MM countries, there will be 5,697,127 cases of chronic insomnia that have been diagnosed as of 2021 Age plays a significant role in how the disease develops. The age group of 20 to 29 years saw the highest number of cases in the US in 2021 with 474,746. Following this, there were 421,996 instances in the US for each of the age groups of 30-39 and 40-49 years France had the greatest diagnosed prevalence of chronic insomnia among the European nations, with 890,539 cases. Germany came in second with 407,108 cases in 2021 Germany reported 207,625 instances of chronic insomnia in females and 199,483 cases in men among the EU5 nations in 2021 Key Chronic Insomnia Companies: Janssen Research & Development, Takeda, and others Key Chronic Insomnia Therapies: Seltorexant, Ramelteon and zolpidem, and others The Chronic Insomnia epidemiology based on gender analyzed that Chronic Insomnia is more prominent in females in comparison to males The Chronic Insomnia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics. Chronic Insomnia Overview Chronic insomnia is a long-term sleep disorder characterized by difficulty falling asleep, staying asleep, or waking up too early, occurring at least three times a week for three months or more. It leads to daytime fatigue, impaired concentration, mood disturbances, and reduced quality of life. Causes can include stress, medical conditions, medications, or poor sleep habits. Get a Free sample for the Chronic Insomnia Market Report: Chronic Insomnia Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Chronic Insomnia Epidemiology Segmentation: The Chronic Insomnia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Prevalence of Chronic Insomnia Prevalent Cases of Chronic Insomnia by severity Gender-specific Prevalence of Chronic Insomnia Diagnosed Cases of Episodic and Chronic Chronic Insomnia Download the report to understand which factors are driving Chronic Insomnia epidemiology trends @ Chronic Insomnia Epidemiology Forecast Chronic Insomnia Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Insomnia market or expected to get launched during the study period. The analysis covers Chronic Insomnia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Chronic Insomnia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Chronic Insomnia Therapies and Key Companies Discover more about therapies set to grab major Chronic Insomnia market share @ Chronic Insomnia Treatment Market Chronic Insomnia Market Drivers Increasing Prevalence Personalization of therapies Chronic Insomnia Market Barriers Issues with diagnosis and poor knowledge Use of off-label drugs High economic burden Scope of the Chronic Insomnia Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Chronic Insomnia Companies: Janssen Research & Development, Takeda, and others Key Chronic Insomnia Therapies: Seltorexant, Ramelteon and zolpidem, and others Chronic Insomnia Therapeutic Assessment: Chronic Insomnia current marketed and Chronic Insomnia emerging therapies Chronic Insomnia Market Dynamics: Chronic Insomnia market drivers and Chronic Insomnia market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Chronic Insomnia Unmet Needs, KOL's views, Analyst's views, Chronic Insomnia Market Access and Reimbursement Table of Contents 1. Chronic Insomnia Market Report Introduction 2. Executive Summary for Chronic Insomnia 3. SWOT analysis of Chronic Insomnia 4. Chronic Insomnia Patient Share (%) Overview at a Glance 5. Chronic Insomnia Market Overview at a Glance 6. Chronic Insomnia Disease Background and Overview 7. Chronic Insomnia Epidemiology and Patient Population 8. Country-Specific Patient Population of Chronic Insomnia 9. Chronic Insomnia Current Treatment and Medical Practices 10. Chronic Insomnia Unmet Needs 11. Chronic Insomnia Emerging Therapies 12. Chronic Insomnia Market Outlook 13. Country-Wise Chronic Insomnia Market Analysis (2019–2032) 14. Chronic Insomnia Market Access and Reimbursement of Therapies 15. Chronic Insomnia Market Drivers 16. Chronic Insomnia Market Barriers 17. Chronic Insomnia Appendix 18. Chronic Insomnia Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
16-05-2025
- Globe and Mail
Anemia in Chronic Kidney Disease Market Set for Significant Growth and Innovation by 2034
Anemia in Chronic Kidney Disease (CKD), a common and debilitating complication resulting from reduced erythropoietin production and iron deficiency, continues to pose serious clinical challenges and an economic burden. DelveInsight's comprehensive report on the Anemia in CKD market sheds light on the evolving understanding and management of this condition, which affects a substantial proportion of patients with moderate to advanced CKD. With improved awareness and screening, earlier diagnosis and intervention are becoming more achievable, especially with the support of emerging biomarkers and treatment guidelines. Innovative therapies such as HIF-PH inhibitors and long-acting erythropoiesis-stimulating agents (ESAs) are shaping a dynamic treatment landscape aimed at improving hemoglobin levels with fewer side effects. DelveInsight's ' Anemia in Chronic Kidney Disease Market Report ' offers an in-depth analysis of the epidemiology, disease burden, and market outlook across key geographies, including the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report highlights current unmet needs, late-stage pipeline therapies, market drivers and barriers, and the key players transforming patient care, making it a vital resource for healthcare stakeholders and innovators in nephrology. Some of the Key Facts of the Anemia in Chronic Kidney Disease Market Report: • The anemia in chronic kidney disease is expected to grow at a significant CAGR by 2034. • In 2023, the United States recorded the highest number of prevalent Anemia in Chronic Kidney Disease (CKD) cases among the 7MM. • The U.S. also accounted for the highest number of treated cases of Anemia in CKD during the same year. • A higher prevalence was noted among individuals aged 60 and above compared to those under 60 in the U.S. • Males with CKD had a 30% higher risk of developing anemia compared to females. • Among the EU4 and the UK, Spain reported the lowest number of anemia in CKD cases in 2023. • In Japan, anemia was one of the most frequently documented outcomes, with prevalence rates ranging from 0% to 95%, depending on CKD severity and dialysis status. • In March 2025, the FDA expanded the approval of Furoscix to include the treatment of edema in patients with chronic kidney disease, including nephrotic syndrome. • In March 2025, scPharmaceuticals received FDA approval for a supplemental new drug application (sNDA) for Furoscix (furosemide injection). This approval expands the drug's use to treat edema in patients with chronic kidney disease (CKD), marking a significant advancement in scPharmaceuticals' portfolio for cardiorenal conditions. • In March 2025, the FDA approved an expanded indication for furosemide injection (Furoscix; scPharmaceuticals, Inc.) to treat edema in adult patients with chronic kidney disease (CKD), including nephrotic syndrome. The expanded treatment is expected to be available by April 2025. This approval follows the FDA's acceptance of the supplemental new drug application in July 2024. • In January 2025, the FDA approved a new indication for semaglutide to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, according to Novo Nordisk. • In November 2024, Unicycive Therapeutics (Nasdaq: UNCY) announced that the FDA has accepted its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC), with a PDUFA target action date set for June 28, 2025. If approved, OLC has the potential to significantly enhance the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients undergoing dialysis. • Leading companies in the anemia in chronic kidney disease market include Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, Acceleron Pharma, Celgene Corporation, and others. • Emerging therapies in the anemia in chronic kidney disease market include DDO-3055, SSS17, BCD-131, BCD-066, Erythropoietin polysialic, CHIP 2, PBI 1402, Sotatercept, and others. • The rising prevalence of anemia in chronic kidney disease, along with continuous advancements in therapeutic options, is fueling the demand for more effective treatment approaches. To know in detail about the anemia in chronic kidney disease market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Anemia In Chronic Kidney Disease Market Forecast Anemia in Chronic Kidney Disease Overview Anemia is a frequent and serious complication of Chronic Kidney Disease (CKD), arising as kidney function declines and the body's ability to produce adequate erythropoietin—a hormone essential for red blood cell production, diminishes. CKD impairs the kidneys' filtering ability, leading to the accumulation of waste and fluids, which further contributes to the onset of anemia. The condition becomes increasingly prevalent in advanced stages of CKD. In the United States, over 37 million adults are estimated to have CKD, and more than one in seven individuals with CKD also suffer from anemia. The risk intensifies as kidney function deteriorates, with nearly all individuals at end-stage kidney failure (when kidney function drops below 15%) experiencing anemia. Certain populations are more susceptible: individuals with CKD and diabetes are at higher risk of developing anemia earlier and in more severe forms. Additionally, people over the age of 60 are more likely to be affected. The progression of CKD-related anemia is typically gradual and may remain asymptomatic in its early stages, making early detection and management crucial for improving patient outcomes. Get a free sample of the anemia in chronic kidney disease market report with key insights and emerging therapies here: Anemia in Chronic Kidney Disease Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Anemia in Chronic Kidney Disease Epidemiology Segmentation: The anemia in chronic kidney disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by: • Total Prevalent Cases of Chronic Kidney Disease • Diagnosed Cases of Anemia in Chronic Kidney Disease • Age-Specific Prevalent Cases of Anemia in Chronic Kidney Disease • Total Prevalent Cases of Anemia in Chronic Kidney Disease • Total Prevalent Cases of Anemia in Different Stages of Chronic Kidney Disease • Treatable Cases of Anemia in Chronic Kidney Disease Download the report to understand which factors are driving anemia in chronic kidney disease epidemiology trends @ Anemia In Chronic Kidney Disease Epidemiology Forecast The anemia in chronic kidney disease drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the anemia in chronic kidney disease market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug. Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share. The report further delves into the anemia in chronic kidney disease pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies. Anemia in Chronic Kidney Disease Market Strengths • The availability of novel oral treatment options, such as daprodustat, offers more convenient and effective routes of administration for patients. • Active research and ongoing clinical trials are enhancing the understanding of the disease and driving innovation in therapeutic strategies. Anemia in Chronic Kidney Disease Market Weaknesses • Patients often struggle to recognize or differentiate the symptoms of anemia from CKD or other related conditions, leading to underreporting. • Healthcare providers, particularly in non-dialysis settings, frequently under-monitor hemoglobin levels and iron stores, resulting in delayed or suboptimal treatment initiation. Scope of the Anemia in Chronic Kidney Disease Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key Anemia In Chronic Kidney Disease Companies: GlaxoSmithKline, Teva Pharmaceuticals, Cipla, Sun Pharmaceuticals, and others. • Key Anemia In Chronic Kidney Disease Therapies: DDO-3055, SSS17, BCD-131, BCD-066, Erythropoietin polysialic, CHIP 2, PBI 1402, Sotatercept, and others. • Anemia In Chronic Kidney Disease Therapeutic Assessment: Anemia in chronic kidney disease, currently marketed, and anemia in chronic kidney disease emerging therapies • Anemia In Chronic Kidney Disease Market Dynamics: Anemia in chronic kidney disease market drivers and anemia in chronic kidney disease market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • Anemia In Chronic Kidney Disease Unmet Needs, KOL's views, Analyst's views, Anemia In Chronic Kidney Disease Market Access and Reimbursement To learn more about the key players and advancements in the anemia in chronic kidney disease treatment landscape, visit the Table of Contents 1. Anemia In Chronic Kidney Disease Market Report Introduction 2. Executive Summary for Anemia In Chronic Kidney Disease 3. SWOT analysis of Anemia In Chronic Kidney Disease 4. Anemia In Chronic Kidney Disease Patient Share (%) Overview at a Glance 5. Anemia In Chronic Kidney Disease Market Overview at a Glance 6. Anemia In Chronic Kidney Disease Disease Background and Overview 7. Anemia In Chronic Kidney Disease Epidemiology and Patient Population 8. Country-Specific Patient Population of Anemia In Chronic Kidney Disease 9. Anemia In Chronic Kidney Disease Current Treatment and Medical Practices 10. Anemia In Chronic Kidney Disease Unmet Needs 11. Anemia In Chronic Kidney Disease Emerging Therapies 12. Anemia In Chronic Kidney Disease Market Outlook 13. Country-Wise Anemia In Chronic Kidney Disease Market Analysis (2020–2034) 14. Anemia In Chronic Kidney Disease Market Access and Reimbursement of Therapies 15. Anemia In Chronic Kidney Disease Market Drivers 16. Anemia In Chronic Kidney Disease Market Barriers 17. Anemia In Chronic Kidney Disease Appendix 18. Anemia In Chronic Kidney Disease Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Globe and Mail
08-05-2025
- Globe and Mail
Neurofibrosarcoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, "Neurofibrosarcoma Pipeline Insight 2025,' report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Neurofibrosarcoma pipeline landscape. It covers the Neurofibrosarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neurofibrosarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Neurofibrosarcoma Pipeline Report to explore emerging therapies, key Neurofibrosarcoma Companies, and future Neurofibrosarcoma treatment landscapes @ Neurofibrosarcoma Pipeline Outlook Report Key Takeaways from the Neurofibrosarcoma Pipeline Report In April 2025, University of Florida conducted a phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors. In April 2025, Alexander Z. Wei, MD announced a phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibody) to doxorubicin for the treatment of patients with advanced soft tissue sarcoma. The investigators believe that doxorubicin, which is currently the standard of care for most advanced sarcomas, could work better when combined with APX005M, which is a type of immunotherapy. DelveInsight's Neurofibrosarcoma Ppipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Neurofibrosarcoma treatment. The leading Neurofibrosarcoma Companies such as Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, Mirati Therapeutics, Astex Pharmaceuticals, Ascentage Pharma Group, Apexigen, Nobelpharma, Pfizer, SpringWorks Therapeutics, NFlection Therapeutics and others. Promising Neurofibrosarcoma Pipeline Therapies such as Ganetespib, Sirolimus, everolimus, bevacizumab, Selumetinib, Tazemetostat, Dasatinib, Doxorubicin, APX005M and others. Stay ahead with the most recent pipeline outlook for Neurofibrosarcoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Neurofibrosarcoma Treatment Drugs Neurofibrosarcoma Emerging Drugs Profile NFX-179: NFlection Therapeutics NFX-179 is an investigational mitogen-activated protein kinase kinase (MEK) inhibitor. NFX-179 is a ""soft"" (metabolically labile) drug, which, when formulated as NFX-179 Gel for topical application, is designed to concentrate at the dermal site of action but degrade in systemic circulation, thereby significantly reducing side effects compared to systemically available MEK inhibitors. Sirolimus: Nobelpharma Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus: FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle. The Neurofibrosarcoma Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Neurofibrosarcoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neurofibrosarcoma treatment. Neurofibrosarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Neurofibrosarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neurofibrosarcoma market. Explore groundbreaking therapies and clinical trials in the Neurofibrosarcoma Pipeline. Access DelveInsight's detailed report now! @ New Neurofibrosarcoma Drugs Neurofibrosarcoma Companies Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, Mirati Therapeutics, Astex Pharmaceuticals, Ascentage Pharma Group, Apexigen, Nobelpharma, Pfizer, SpringWorks Therapeutics, NFlection Therapeutics and others. Neurofibrosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Neurofibrosarcoma Products have been categorized under various Molecule types such as Small molecule Cell Therapy Peptides Polymer Small molecule Gene therapy Unveil the future of Neurofibrosarcoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Neurofibrosarcoma Market Drivers and Barriers Scope of the Neurofibrosarcoma Pipeline Report Coverage- Global Neurofibrosarcoma Companies- Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, Mirati Therapeutics, Astex Pharmaceuticals, Ascentage Pharma Group, Apexigen, Nobelpharma, Pfizer, SpringWorks Therapeutics, NFlection Therapeutics and others. Neurofibrosarcoma Pipeline Therapies- Ganetespib, Sirolimus, everolimus, bevacizumab, Selumetinib, Tazemetostat, Dasatinib, Doxorubicin, APX005M and others. Neurofibrosarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Neurofibrosarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Neurofibrosarcoma Drug development? Find out in DelveInsight's exclusive Neurofibrosarcoma Pipeline Report—access it now! @ Neurofibrosarcoma Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Neurofibrosarcoma: Overview Pipeline Therapeutics Therapeutic Assessment Neurofibrosarcoma– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Sirolimus: Nobelpharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) ASTX727: Astex Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I/II) MRTX1719: Mirati Therapeutics Drug profiles in the detailed report….. Preclinical Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Neurofibrosarcoma Key Companies Neurofibrosarcoma Key Products Neurofibrosarcoma- Unmet Needs Neurofibrosarcoma- Market Drivers and Barriers Neurofibrosarcoma- Future Perspectives and Conclusion Neurofibrosarcoma Analyst Views Neurofibrosarcoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 9650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
